Table 1. Baseline characteristics and univariate analysis of risk factors for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.

Parameter	The serious bleeding group (n=14)	The non-serious bleeding group (n=23)	p value
Age (years, mean (SD))	40.6 (4.7)	40.8 (4.3)	0.845
BMI (kg/m2, mean (SD))	20.7 (3.1)	21.5 (4.4)	0.583
Nulliparous (n (%; 95% CI))	7 (50%)	12 (52%)	1.000
Severe dysmenorrhea	14(100%)	20(87%)	0.275
Prior therapy	6(43%)	10(43%)	1.000
Previous cesarean delivery	0(0%)	5(21.7%)	0.135
Previous endometrial curettage	5(36%)	11(48%)	0.471
Presence of hypermenorrhea	8(57%)	13(57%)	0.970
Minimum hemoglobin level before DNG treatment(g/dl, mean(SD))	11.2(1.3)	12.0(1.2)	0.074
Minimum hemoglobin level after or during DNG treatment(g/dl, mean(SD))	8.3(1.1)	11.8(1.2)	0.000
Duration of treatment with DNG(month, IQR, range)	3.5(IQR, 6.8; range, 2.0-24.0)	15.0(IQR, 33.0; range, 3.0-96.0)	0.001
The presence of endometriotic cyst	4(29%)	14(61%)	0.091
The presence of leiomyoma	4(29%)	11(48%)	0.314
Median maximum diameter of adenomyosis associated lesion (mm, IQR, range)	37.5 (IQR, 13.4; range, 22.9 - 76.3)	33.0 (IQR, 26.4; range, 16.0 - 72.1)	0.056
Median maximum distance between uppermost part of uterine cavity and internal os (mm, IQR, range)	87.6 (IQR , 40.5; range, 46.0 - 124.6)	73.0 (IQR, 31.4; range, 55.0 - 132.3)	0.313
Median maximum diameter of myometrial wall thickness (mm, IQR, range)	45.3 (IQR, 12.9; range, 30.4 - 76.3)	41.8 (IQR, 32.1; range, 21.0 - 72.1)	0.090
Subtype I Adenomyosis	8(57%)	4(17%)	0.027